Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone hexacetonide
Drug ID BADD_D02274
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Prescription
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00985
MeSH ID C005900
PubChem ID 21826
TTD Drug ID Not Available
NDC Product Code 52128-177; 46439-8728; 59137-570
Synonyms triamcinolone hexacetonide | 9-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, 21-(3,3-dimethylbutyrate) | Aristospan
Chemical Information
Molecular Formula C30H41FO7
CAS Registry Number 5611-51-8
SMILES CC1(OC2CC3C4CCC5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)COC(=O)CC(C)(C)C)C)O)F)C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fat tissue increased08.01.03.009--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Gastrointestinal perforation07.04.04.001--Not Available
Glaucoma06.03.01.002--
Glucose tolerance impaired14.06.02.001; 05.06.02.001--
Glycosuria20.02.01.005--
Headache17.14.01.001--
Hepatomegaly09.01.05.001--Not Available
Hiccups22.02.04.002; 07.01.06.009--
Hirsutism05.05.01.005; 23.02.04.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertrichosis23.02.04.002--
Hypertrophic cardiomyopathy03.07.02.004; 02.04.01.002--Not Available
Hypokalaemic syndrome14.05.03.003--Not Available
Hypopituitarism05.03.02.001--
Hypothalamo-pituitary disorder05.03.04.003--Not Available
Impaired healing08.03.02.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Injection site infection08.02.03.019; 12.07.03.008; 11.01.08.005--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Large intestine perforation12.02.03.005; 07.04.06.005--
Malaise08.01.01.003--
Meningitis17.06.03.001; 11.01.03.001--
Menstruation irregular21.01.01.005; 05.05.01.008--
Mood swings19.04.03.001--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages